# Defining the Optimal Hormonal Replacement Therapy in Turner Syndrome

> **NCT00134745** · PHASE4 · COMPLETED · sponsor: **Line Cleemann** · enrollment: 43 (actual)

## Conditions studied

- Turner Syndrome

## Interventions

- **DRUG:** estradiol

## Key facts

- **NCT ID:** NCT00134745
- **Lead sponsor:** Line Cleemann
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** 2013-03
- **Final completion:** 2013-03
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2013-06-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00134745

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00134745, "Defining the Optimal Hormonal Replacement Therapy in Turner Syndrome". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00134745. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*